Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Fish and Richardson
US Department of Justice
Federal Trade Commission
Julphar
QuintilesIMS

Generated: September 18, 2019

DrugPatentWatch Database Preview

Patent: 7,767,689

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,767,689
Title:Carboline derivatives useful in the treatment of cancer
Abstract: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.
Inventor(s): Moon; Young-Choon (Belle Mead, NJ), Cao; Liangxian (Parlin, NJ), Tamilarasu; Nadarajan (Edison, NJ), Qi; Hongyan (Plainsboro, NJ), Choi; Soongyu (Skillman, NJ), Lennox; William Joseph (South Plainfield, NJ), Corson; Donald Thomas (Annandale, NJ), Hwang; Seongwoo (Edison, NJ), Davis; Thomas (South Orange, NJ)
Assignee: PTC Therapeutics, Inc. (South Planfield, NJ)
Application Number:11/107,783
Patent Claims:see list of patent claims

Details for Patent 7,767,689

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Try a Free Trial PTC Therapeutics, Inc. (South Planfield, NJ) 2024-03-15 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Try a Free Trial PTC Therapeutics, Inc. (South Planfield, NJ) 2024-03-15 RX search
Eli Lilly And Co CYRAMZA ramucirumab INJECTABLE;INJECTION 125477 001 2014-04-21   Try a Free Trial PTC Therapeutics, Inc. (South Planfield, NJ) 2024-03-15 RX search
Eli Lilly And Co CYRAMZA ramucirumab INJECTABLE;INJECTION 125477 002 2014-04-21   Try a Free Trial PTC Therapeutics, Inc. (South Planfield, NJ) 2024-03-15 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Federal Trade Commission
QuintilesIMS
Citi
Chubb
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.